# OnCo record nct07397338 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07397338/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07397338", "NCT07397338" ;
  schema:name "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Daraxonrasib, Elironrasib, Zoldonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07397338/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07397338> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-01-30" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> .